U.S. Machinery Stock News

NasdaqGS:CME
NasdaqGS:CMECapital Markets

CME Group (CME) Stock Looks Fairly Valued While Earnings Still Look Rich

CME Group stock has delivered a 55.1% gain over the past five years, yet current valuation checks and pricing signals suggest the shares may now sit closer to fair value rather than being a clear bargain. Recent product launches and record activity in key contracts are drawing attention, while the intrinsic value estimate and market multiples offer a more restrained read on potential upside. A 55.1% return over five years points to solid long term wealth creation, which raises the bar for...
NYSE:ARMK
NYSE:ARMKHospitality

Aramark (ARMK) Could Be 5% Undervalued Following Its New Campus Dining Deal

Aramark (ARMK) shares are in focus after the company confirmed a quarterly dividend of $0.12 per share and announced a new long-term campus dining partnership with the University of Colorado Colorado Springs. See our latest analysis for Aramark. At a share price of $56.22, Aramark has seen short term momentum ease with the 7 day share price return down 2.06%, although the 90 day share price return of 22.80% and 5 year total shareholder return of 141.27% show a much stronger longer term...
NYSE:MSI
NYSE:MSICommunications

Motorola Solutions (MSI) Stock Looks Above Fair Value As Its 105% Run Continues

Motorola Solutions stock has delivered a 104.5% return over the past 5 years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than a clear bargain. Over the last 5 years, Motorola Solutions has returned 104.5%. This puts recent buyers in profit and raises the bar for what needs to happen next to justify the current share price. Expectations around ongoing demand for Motorola Solutions' mission...
NYSE:OGS
NYSE:OGSGas Utilities

ONE Gas (OGS) Reports Higher Q2 Earnings, Is It Still Below Fair Value?

ONE Gas (OGS) shares are in focus after the company reported second quarter 2026 results, which showed higher net income and earnings per share on lower sales, alongside an affirmed quarterly dividend of $0.68 per share. See our latest analysis for ONE Gas. ONE Gas shares recently moved lower in the short term, with the 7 day share price return down 4.18% and the 90 day share price return down 10.08%. At the same time, the 1 year total shareholder return of 10.07% and 5 year total shareholder...
NasdaqGS:CCC
NasdaqGS:CCCSoftware

CCC Intelligent Solutions Holdings (CCC) After Raised Guidance And Results, What Valuation Looks Like

CCC Intelligent Solutions Holdings (CCC) drew fresh investor attention after reporting second quarter and half year 2026 results along with new revenue guidance for the third quarter and full year. See our latest analysis for CCC Intelligent Solutions Holdings. The earnings release and fresh guidance have come after a strong short term rebound in CCC Intelligent Solutions Holdings, with a 30 day share price return of 13.44% and a 90 day gain of 23.63%. However, the share price is still down...
NYSE:KBR
NYSE:KBRProfessional Services

Is KBR (KBR) Undervalued As Record Backlog And 2026 Guidance Support Its Spin Off Plan?

KBR (KBR) recently highlighted a record backlog in its Sustainable Technology Solutions segment, reaffirmed full year 2026 revenue guidance, and advanced plans to spin off Mission Technologies as Trinzic with designated leadership in place. See our latest analysis for KBR. At a share price of US$37.83, KBR has seen a 2.0% 1 day share price return and a 7.8% 90 day share price return, while the 1 year total shareholder return has declined 22.6%. This suggests that short term momentum has...
NYSE:NVO
NYSE:NVOPharmaceuticals

Novo Nordisk (NYSE:NVO) Stock May Be Below Fair Value On ZEUS Trial Fallout

After a three year stretch where Novo Nordisk stock has declined 50.5%, the valuation picture now looks more supportive than the share price performance suggests, helped by a strong set of value checks even as recent news has weighed on sentiment. The 50.5% fall over three years has reset expectations and leaves investors asking whether the current price already reflects concerns around the business. The failed ZEUS trial for ziltivekimab may cap confidence in Novo Nordisk's pipeline driven...
NasdaqCM:XPEL
NasdaqCM:XPELAuto Components

Karat Packaging Stock And 2 U.S. Small Caps With Pricing Power on Import Costs

Fresh tariffs, legal challenges and questions over trade rules are reshaping the outlook for smaller U.S. companies that rely on imported inputs. For investors, this creates both risk and potential opportunity as tariffs of 10% and 12.5% on goods from 60 trading partners feed into costs, pricing power and margins. This article focuses on three U.S. small cap stocks that appear positioned to be positively exposed to the current tariff dispute. By the end, you will have a clearer view of how...
NYSE:CVSA
NYSE:CVSAConsumer Services

Covista (CVSA) Leadership Shakeup Draws Focus As Fair Value Narrative Stays Above The Stock

Recent leadership changes at Covista (CVSA) are drawing fresh attention to the stock, after the company created a new Performance Acceleration Office and reshaped responsibilities across its Medical and Veterinary segment. See our latest analysis for Covista. Covista’s recent leadership reshuffle comes as the stock trades at US$129.89, with a 1-day share price return of 1.88% and a 90-day share price return of 12.64%, alongside a 3-year total shareholder return of 190.91% that points to...
NYSE:MAC
NYSE:MACRetail REITs

Macerich (MAC) Could Be 50% Undervalued On FFO Beat And Dividend Reaffirmation

Macerich (MAC) is back in focus after reporting second quarter 2026 funds from operations and revenue that topped consensus estimates, alongside a reaffirmed quarterly dividend of $0.17 per common share. See our latest analysis for Macerich. At a recent share price of US$25.62, Macerich has given investors a strong year to date share price return of 38.34%, backed by a 55.04% total shareholder return over the past year and a 126.38% total shareholder return over three years. This points to...
NYSE:VYX
NYSE:VYXSoftware

NCR Voyix (VYX) Stock Looks Fully Priced After Years Of Weak Returns

NCR Voyix stock has fallen sharply over the past several years, yet the current market multiples still suggest the shares may be pricing in a lot of optimism. With a mixed valuation score and a long period of weak returns, investors are left weighing whether the current price offers enough compensation for the risks. NCR Voyix has delivered a decline of 65.5% over the past 5 years, which points to a long stretch where shareholders have not been rewarded. Future cash generation from NCR...
NYSE:UAMY
NYSE:UAMYMetals and Mining

Will UAMY’s Shift To Self-Mined Antimony Ore Redefine Its Cost Structure And Supply Resilience?

Earlier this year, United States Antimony Corporation reported a company-wide update on its mining activities in Alaska, Montana, and Canada, confirming progress on multiple claims such as Ester Dome, Stibnite Creek, and Nolan Creek and outlining plans to begin mining operations later in 2026. The company also indicated that 2026 will be the first year it uses antimony ore from its own mines to fulfill customer contracts, a shift that could reshape its cost structure and supply reliability...
NYSE:KNX
NYSE:KNXTransportation

Knight Swift Transportation Holdings (KNX) Could Be 17% Undervalued After Q2 Earnings

Why Knight-Swift Transportation Holdings Stock Is Back in Focus After Q2 Earnings Knight-Swift Transportation Holdings (KNX) moved back onto investor watchlists after reporting second quarter 2026 results on 22 July, with sales, revenue and net income all higher than the same period in 2025. See our latest analysis for Knight-Swift Transportation Holdings. The Q2 earnings release has come after a strong run in Knight-Swift Transportation Holdings shares, with a 37.12% year to date share price...
NYSE:DGX
NYSE:DGXHealthcare

Quest Diagnostics (DGX) Lifts 2026 Outlook As Investors Ask If The Stock Is Fully Valued

Quest Diagnostics (DGX) stock has been in focus after the company reported second quarter and six month 2026 results and raised its full year revenue and earnings guidance, indicating that the company now expects higher financial performance. See our latest analysis for Quest Diagnostics. Quest Diagnostics shares have picked up pace over 2026, with a 1‑month share price return of 8.34%, a 90‑day gain of 23.58%, and a 1‑year total shareholder return of 37.26%. This reflects recent share price...
NYSE:KOS
NYSE:KOSOil and Gas

Kosmos Energy (KOS) Stock Still Looks Cheap Even After Big Gains

Kosmos Energy stock has surged year to date, yet its valuation checks still flag the shares as leaning cheap on several measures. For investors, that mix of strong price momentum and an apparently supportive valuation is likely to be the key focus right now. Year to date, Kosmos Energy has returned 171.1%, which puts the recent share price strength front and center for anyone assessing what happens next. Future cash generation from existing assets can support the current share price...
NYSE:BROS
NYSE:BROSHospitality

Dutch Bros (BROS) Heads Into Q2 Earnings With Expansion In Focus On Valuation

Why Dutch Bros stock is in focus ahead of Q2 earnings Investor attention on Dutch Bros (BROS) is building ahead of its Q2 2026 earnings release on August 5. Analysts expect year-over-year growth in both revenue and earnings. At the same time, Dutch Bros continues to add new shops in markets like South Carolina, Georgia, Illinois, and North Carolina. This keeps expansion and unit economics at the center of the story for anyone following the stock. See our latest analysis for Dutch Bros. Dutch...
NYSE:PNC
NYSE:PNCBanks

Is PNC’s US$2 Billion Branch and Cybersecurity Push Reframing the Investment Case for PNC (PNC)?

PNC Bank recently opened its 50th new branch in Hialeah, Florida, marking a key milestone in its coast-to-coast build-out of more than 300 locations and an approximately US$2.00 billion program to expand and renovate its U.S. branch network by 2030. This branch rollout, alongside the appointment of Christian Winward as chief information security officer, highlights PNC’s continued emphasis on both physical presence and cybersecurity as it scales its national franchise. Now, we’ll explore how...
NYSE:AUB
NYSE:AUBBanks

How Investors Are Reacting To Atlantic Union Bankshares (AUB) New Subordinated Debt And Ongoing Dividends

Atlantic Union Bankshares recently completed a US$250,000,000 fixed-to-floating rate subordinated notes offering due 2036 and, in July 2026, declared quarterly dividends on both its common stock and 6.875% Series A preferred shares. Together, the new junior unsecured notes and continued dividend payments highlight the company’s current focus on funding flexibility while maintaining ongoing cash returns to shareholders. We’ll now examine how the new US$250,000,000 subordinated debt issuance...
NYSE:GE
NYSE:GEAerospace & Defense

The Bull Case For General Electric (GE) Could Change Following Surging Aerospace Engine Services Revenue Growth

In recent days, GE Aerospace reported that its Commercial Engines & Services segment delivered a 27% revenue increase in Q2 2026, supported by strong services, spare parts demand, LEAP engine deliveries, and a series of significant engine and long-term service agreements with major airlines. At the same time, management highlighted persistent cost and margin pressures, meaning investors are weighing robust top-line and cash generation against a more gradual profitability improvement path...
NYSE:DELL
NYSE:DELLTech

Is Dell Technologies (DELL) Fairly Valued After Its AI Infrastructure Wins?

Dell Technologies (DELL) has moved into the spotlight after a run of AI focused infrastructure deals, including the Volta AI factory contract, Texas A&M’s IGNITE platform and an expanded distribution agreement with D&H Distributing. See our latest analysis for Dell Technologies. The recent AI infrastructure announcements come on top of a powerful run in Dell Technologies stock, with a 90 day share price return of 95.67% and year to date share price return of 265.63%, while the 1 year total...
NasdaqGS:POWI
NasdaqGS:POWISemiconductor

Power Integrations (POWI) Extends PowiGaN To 2200 V, Is The Stock Fully Priced?

Why Power Integrations Stock Is Back in Focus After Its PowiGaN Update Power Integrations (POWI) just announced that its PowiGaN gallium nitride technology now supports up to 2,200 V, positioning the company for high-voltage data centers, electric vehicles, renewables and HVDC infrastructure. This rating sits above other commercially available GaN offerings described in the announcement. For you as an investor, the key question is how this expanded voltage range could influence Power...
NYSE:SO
NYSE:SOElectric Utilities

Southern (SO) Earnings And $2.4b Notes Put Fair Value Back In Focus

Southern (SO) has drawn fresh attention after announcing and then completing two Rule 144A convertible step up note offerings totaling about $2.4b, alongside reporting its second quarter 2026 earnings results. See our latest analysis for Southern. Southern’s recent earnings update and the $2.4b in new convertible step up notes arrive as momentum cools slightly in the short term. The company has seen a 30 day share price return decline of 4.83%, yet the 5 year total shareholder return of...
NasdaqCM:EGBN
NasdaqCM:EGBNBanks

Banking Sector Stocks To Watch If Rate Hike Talk Gains Ground

Rising rate talk is back on the table after Minneapolis Fed President Neel Kashkari pushed for an immediate hike, and that has put fresh attention on Banking Sector Stocks. Higher policy rates can lift funding costs and weigh on equity valuations, yet they can also reshape how banks earn from lending and deposits. For investors, one key question is which stocks appear better positioned if this tightening view gains traction. This article walks through 3 stocks from our Banking Sector Stocks...
NasdaqGM:NRIX
NasdaqGM:NRIXBiotechs

How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche

Nurix Therapeutics recently reported two key milestones: a US$10 million payment under its Sanofi collaboration tied to a first-in-human STAT6 degrader trial and the first patient enrolled in a global Phase 3 DAYBreak CLL-306 study of bexobrutideg with Roche in relapsed or refractory CLL/SLL. These updates highlight how Nurix’s DEL-AI discovery platform and partnership model can convert early discovery work into late-stage trials and substantial future milestone eligibility, while preserving...